Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

4Total
P 1 (2)
P 2 (2)

Trial Status

Not Yet Recruiting2
Enrolling By Invitation1
Active Not Recruiting1
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07249905Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

NCT02180724Phase 2Active Not RecruitingPrimary

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT07259122Phase 2Not Yet RecruitingPrimary

A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia

NCT07173790Enrolling By Invitation

Watch and Wait or Worry and Wait in Indolent Lymphoma

NCT07169565Phase 1Not Yet RecruitingPrimary

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Showing all 5 trials

Research Network

Activity Timeline